Norges Bank Ambrx Biopharma Inc. Transaction History

Norges Bank

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.66 - $16.46 $477,953 - $1.03 Million	-62,396 Closed	0 $0
Q2 2022 Aug 14, 2023	BUY	$2.53 - $4.35 $157,861 - $271,422	62,396 New	62,396 $165,000
Q1 2022 May 12, 2023	BUY	$4.07 - $9.0 $284,900 - $630,000	70,000 New	70,000 $288,000
Q1 2022 May 09, 2022	SELL	$4.07 - $9.0 $284,900 - $630,000	-70,000 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$8.11 - $13.91 $567,700 - $973,700	70,000 New	70,000 $632,000
Q3 2021 Nov 14, 2022	BUY	$13.31 - $22.53 $931,700 - $1.58 Million	70,000 New	70,000 $945,000
Q3 2021 Nov 05, 2021	SELL	$13.31 - $22.53 $931,700 - $1.58 Million	-70,000 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$15.95 - $19.6 $1.12 Million - $1.37 Million	70,000 New	70,000 $1.37 Million

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.